An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer

ObjectivesOur goal is to determine the ability of multi-parametric magnetic resonance imaging (mpMRI) to differentiate muscle invasive bladder cancer (MIBC) from non-muscle invasive bladder cancer (NMIBC).MethodsPatients underwent mpMRI before tumour resection. Four MRI sets, i.e. T2-weighted (T2W) + perfusion-weighted imaging (PWI), T2W plus diffusion-weighted imaging (DWI), T2W + DWI + PWI, and T2W + DWI + PWI + dif-fusion tensor imaging (DTI) were interpreted qualitatively by two radiologists, blinded to histology results. PWI, DWI and DTI were also analysed quantitatively. Accuracy was determined using histopathology as the reference standard.ResultsA total of 82 tumours were analysed. Ninety-six percent of T1-labeled tumours by the T2W + DWI + PWI image set were confirmed to be NMIBC at histopathology. Overall accuracy of the complete mpMRI protocol was 94% in differentiating NMIBC from MIBC. PWI, DWI and DTI quantitative parameters were shown to be significantly different in cancerous versus non-cancerous areas within the bladder wall in T2-labelled lesions.ConclusionsMpMRI with DWI and DTI appears a reliable staging tool for bladder cancer. If our data are validated, then mpMRI could precede cystoscopic resection to allow a faster recognition of MIBC and accelerated treatment pathways.Key Points• A critical step in BCa staging is to differentiate NMIBC from MIBC.• Morphological and functional sequences are reliable techniques in differentiating NMIBC from MIBC.• Diffusion tensor imaging could be an additional tool in BCa staging.

[1]  D. Collins,et al.  Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors , 2007, Journal of magnetic resonance imaging : JMRI.

[2]  C. la Vecchia,et al.  The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. , 2016, European urology.

[3]  M. Abbod,et al.  Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. , 2013, The Journal of urology.

[4]  Y. Lotan,et al.  The economics of bladder cancer: costs and considerations of caring for this disease. , 2014, European urology.

[5]  M. Bulut,et al.  The value of diffusion-weighted MRI in the diagnosis of malignant and benign urinary bladder lesions. , 2011, The British journal of radiology.

[6]  J. Catto,et al.  Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. , 2013, European urology.

[7]  A. Laupacis,et al.  Longer wait times increase overall mortality in patients with bladder cancer. , 2009, The Journal of urology.

[8]  M. Schostak,et al.  Hematogenous Tumor Cell Spread Following Standard Transurethral Resection of Bladder Carcinoma. , 2016, European urology.

[9]  Jian Guan,et al.  Multiparametric 3-T MRI for differentiating low-versus high-grade and category T1 versus T2 bladder urothelial carcinoma. , 2015, AJR. American journal of roentgenology.

[10]  M. Babjuk,et al.  Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. , 2017, European urology.

[11]  Yan Guo,et al.  Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. , 2016, AJR. American journal of roentgenology.

[12]  Laurence Collette,et al.  Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. , 2002, European urology.

[13]  A. Aprikian,et al.  Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. , 2006, European urology.

[14]  Tarek El-Diasty,et al.  Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. , 2009, Radiology.

[15]  A. Jemal,et al.  International variations in bladder cancer incidence and mortality. , 2014, European urology.

[16]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[17]  Jurgen J Fütterer,et al.  Multiparametric MRI of the bladder: ready for clinical routine? , 2014, AJR. American journal of roentgenology.

[18]  A. Cox,et al.  Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. , 2015, JAMA oncology.

[19]  Carlo Catalano,et al.  In vivo 3D neuroanatomical evaluation of periprostatic nerve plexus with 3T-MR Diffusion Tensor Imaging. , 2013, European journal of radiology.

[20]  J. Kawamura,et al.  A new staging criterion for bladder carcinoma using gadolinium‐enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography , 2000, BJU international.

[21]  Adilson Prando,et al.  Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade , 2009 .

[22]  J. Gschwend,et al.  An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. , 2010, European urology.

[23]  P. Carroll,et al.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. , 1994, Radiology.

[24]  G J M Parker,et al.  Comparison of dynamic contrast‐enhanced MRI and dynamic contrast‐enhanced CT biomarkers in bladder cancer , 2011, Magnetic resonance in medicine.

[25]  D. Bluemke,et al.  Dynamic MRI of bladder cancer: evaluation of staging accuracy. , 2005, AJR. American journal of roentgenology.